Merck KGaA: Kley's Fit-for-2018 overhaul turned Serono debt into record results

By 2007 the world's oldest pharma and chemicals company looked tired: the last drug developed entirely in its own labs, the blood-pressure medicine Concor, dated to 1988, and its pipeline was thinning against rivals like Bayer and Boehringer. To leap into biotech, Merck had agreed in September 2006 to buy Switzerland's Serono for $13.3 billion, a deal that closed in early 2007 and piled debt onto a family-controlled company. In April 2007 Karl-Ludwig Kley, a Lufthansa CFO and ex-Bayer executive, took over as chairman from Michael Römer.

Kley's cure was radical for a company owned by the Merck family since 1668. In October 2007 he closed the $7.0 billion sale of the generics division — some 4,000 employees — to Mylan, using the proceeds to pay down the Serono debt. He refilled key management posts, refocused the organization and folded the restructuring into what became the group-wide 'Fit for 2018' transformation and efficiency program. The path was not smooth: the European Medicines Agency rejected Erbitux for lung cancer in 2009 and voted against MS drug Cladribine in 2010, and the restructuring cost many jobs.

The payoff arrived in stages. Merck added Millipore in 2010 to build a life-science arm, and in 2011 revenue broke €10 billion for the first time, rising 10.6% to €10.2 billion, with Rebif sales of €1.69 billion and Erbitux at €855 million. By 2013 the Fit for 2018 program had pushed EBITDA pre one-time items up 9.7% to a record €3.3 billion, profit after tax more than doubled to €1.2 billion and net financial debt was cut 84.1% to €306.6 million — room, as Kley put it, to grow again, also through bigger acquisitions.

Revenue topped €10bn for the first time in 2011 (€10.2bn, +10.6%); by 2013 EBITDA hit a record €3.3bn, profit after tax doubled to €1.2bn and net debt fell 84%.

It is a textbook European family-company turnaround: an outsider CFO brought in by the owning family to do what insiders had postponed.

The Mylan generics divestment shows how to finance a transformational acquisition with a decisive portfolio sale.

Fit for 2018 became a rare long-horizon German restructuring program that management publicly tracked to completion.

Record 2011 revenue and record 2013 EBITDA prove the fix was operational, not just financial engineering.

Pipeline failures (Erbitux 2009, Cladribine 2010) show the turnaround succeeded despite, not because of, R&D luck.

When a big acquisition loads the balance sheet, fund it by selling what no longer fits, then run a multi-year efficiency program leadership publicly owns and tracks to completion.

Kley stayed until April 2016, adding Sigma-Aldrich in 2015 and handing a roughly doubled company — about €15 billion in sales and 50,000 employees — to Stefan Oschmann. The debt that once threatened the group was reduced to a fraction of earnings, the dividend was raised in step with profits, and Merck KGaA re-established itself as a three-pillar group spanning healthcare, life science and performance materials. Belén Garijo later continued the healthcare refocus, and the Darmstadt-based group remains controlled by the Merck family.